InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.48
(
0.80%
)
Bitcoin
64,231.68
(
0.96%
)
Post# of 216
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

TREND1

Send PM Follow Ignore
Followers 415
Posts 52354
Boards Moderated 13
Alias Born 12/16/2001

TREND1

Member Level

Re: None

Thursday, 05/11/2017 12:09:47 PM

Thursday, May 11, 2017 12:09:47 PM

Post# of 216
5/11 MannKind Q1 revenue disappoints, shares down 15%


•MannKind (MNKD -14.7%) Q1 results ($M): Revenue: 3.0, Commercial Product Sales: 1.2, Bulk Insulin Sales: 1.8.

•Net Loss: (16.3) (+34.5%); Loss/Share: (0.17) (+41.4%).

•FDA decision on Afrezza labeling update expected by September 30.

•Investors are expected some daylight regarding Afrezza sales. Consensus view for Q2 and full-year are $2.8M and $28M, respectively.





https://seekingalpha.com/news/3266525-mannkind-q1-revenue-disappoints-shares-15-percent?uprof=51#email_link

MAIN BOARD http://investorshub.advfn.com/TRADING-3X-TNA-TQQQ-SPXL-RUS-2000-FUTURES-12981/

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up